The copper IUD model T-Cu 380A has shown the best performance when compared with other copper and inert IUDs in studies carried out in the U.S.A., but it had not been tried out in developing countries yet. T-Cu 380A and Lippes loop C were inserted at random in 328 healthy parous women, in Campinas, SP, Brasil. Forty-five percent of the T-Cu 380A insertions and 40% of the Lippes loop insertions were performed by trained midwives. No pregnancies occurred in 1419 woman-months of use of T-Cu 380A, against 5 pregnancies in 1454 woman-months of use of Lippes loop. The difference was significant at the 5% level. No other significant differences were found. The continuation rate after one year of use was 82.5 for the T-Cu 380A and 75.1 for the Lippes loop. These results suggest that the performance of the T-Cu 380A in developing countries could be similar to the one observed in the United States, provided that the users are carefully selected and that an adequate insertion technique is followed.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0010-7824(82)90071-3DOI Listing

Publication Analysis

Top Keywords

t-cu 380a
28
lippes loop
20
380a lippes
8
developing countries
8
t-cu
7
380a
7
lippes
5
loop
5
randomized clinical
4
clinical study
4

Similar Publications

[Posplacenta intrauterine device. Guide wires not visible].

Ginecol Obstet Mex

March 2012

Departamento de Biología de la Reproducción, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, México, DF.

Background: Little information exists about the follow- up of the strings of intrauterine device (IUD) applied posplacenta. When the strings are of 10 cm in length are within the uterine cavity should be visible after postpartum involution.

Objective: To know the incidence of visible strings of intrauterine device (IUD) after posplacental insertion and to establish guidelines of follow-up when strings are not seen.

View Article and Find Full Text PDF

Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women.

Contraception

July 1999

Instituto Chileno de Medicina Reproductiva, Consultorio de Planificación Familiar, Santiago, Chile.

The contraceptive efficacy and safety of a progesterone-releasing vaginal ring (PVR) manufactured in Chile were compared to that of the Copper T 380A IUD (T-Cu) in nursing women enrolled at three Chilean clinics. A total of 285 volunteers chose to use the PVR and 262 the T-Cu. Plasma progesterone levels attained with the ring decreased from 25 to 14 nmol/L from month 1 to month 3 of use.

View Article and Find Full Text PDF

Norplant((R)) implants and progesterone vaginal rings do not affect maternal bone turnover and density during lactation and after weaning.

Hum Reprod

October 1999

Instituto Chileno de Medicina Reproductiva, Consultorio de Planificación Familiar, J.V. Lastarria 29, Depto. 101, Santiago, Chile.

Bone density and turnover was assessed in a longitudinal study of healthy lactating women who initiated use of Norplant((R)) implants (NOR, n = 29), progesterone vaginal rings (PVR, n = 28) or Copper T 380A intrauterine devices (T-Cu, n = 51, control group) around day 60 postpartum. Bone density, serum calcium, phosphorus, alkaline phosphatases, parathyroid hormone (PTH), follicle stimulating hormone (FSH), oestradiol and prolactin, and urinary hydroxyproline and creatinine were measured at postpartum months 1 (PM1), and 12 (PM12) and 6 or 12 months after weaning; at month 6 postpartum (PM6) serum and urine tests alone were performed. Baseline characteristics and lactation performance were similar between groups.

View Article and Find Full Text PDF

Modern trends in contraception.

Obstet Gynecol Clin North Am

December 1990

Department of Gynecology-Obstetrics, Henry Ford Hospital, Detroit, Michigan.

Substantial improvements have been made in oral contraceptives, a new injectable contraceptive (Norplant), and the intrauterine device (IUD). Major risks with oral contraceptives have declined substantially, and a number of noncontraceptive health benefits have been discovered. Norplant is probably the first new contraceptive in recent years, and offers long-term contraception with high efficacy and modest risks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!